Business Context and Reporting Period
Company: Oxygen Biotherapeutics, Inc. (Note: Filing metadata referenced "Tenax Therapeutics," but the document content identifies the registrant as Oxygen Biotherapeutics, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 2011
Business Overview: A development-stage biotechnology company focused on oxygen delivery to tissue. Key product candidates include Oxycyte (an intravenous oxygen carrier for traumatic brain injury), Dermacyte (topical cosmetic products), and Wundecyte (wound-healing gel). The company has no approved drug products for sale.
Key Financial Metrics
| Metric | Three Months Ended Jan 31, 2011 | Nine Months Ended Jan 31, 2011 | Balance Sheet (Jan 31, 2011) |
|---|---|---|---|
| Revenue | $52,562 | $95,543 | - |
| Net Loss | $(2,544,187) | $(7,598,423) | - |
| Net Loss Per Share (Basic/Diluted) | $(0.11) | $(0.33) | - |
| Cash and Cash Equivalents | - | - | $522,340 |
| Total Current Assets | - | - | $1,316,254 |
| Total Current Liabilities | - | - | $1,704,697 |
| Working Capital | - | - | $(388,443) |
| Long-Term Debt (Notes Payable) | - | - | $2,041,694 |
| Accumulated Deficit | - | - | $(89,066,001) |
Material Changes vs. Prior Period
- Revenue Growth: Product revenue increased 71% for the three months and 156% for the nine months ended January 31, 2011, compared to the prior year. This was driven by the launch of new Dermacyte products and an initial order from a new European distributor (Dermacyte Switzerland Ltd).
- Operating Expenses:
- Marketing & Sales: Increased 169% (3-month) and 350% (9-month) due to expanded sales force, advertising, and trade show costs.
- General & Administrative (G&A): Increased 20% for the three months but decreased 4% for the nine months. The 3-month increase included a $550,000 accrual for potential Section 409A tax liabilities and a $170,000 severance payment, offset by reductions in stock-based compensation and travel costs.
- R&D: Decreased 51% for the three months due to reduced preclinical costs, though Phase II-b clinical trial costs for Oxycyte increased. For the nine months, R&D was relatively flat (up 2%).
- Debt Structure: The company entered a Note Purchase Agreement with Vatea Fund, issuing senior unsecured promissory notes with a final payment premium. As of January 31, 2011, $2.0 million in principal notes were issued under this agreement.
- Inventory Impairment: Recorded a $162,326 charge for the impairment of clinical grade Oxycyte inventory due to stability testing results.
Guidance, Outlook, Risks, and Contingencies
- Liquidity and Going Concern: Management states that existing cash, combined with remaining availability under the Note Purchase Agreement, is sufficient to fund operations through June 30, 2011. The company has an accumulated deficit of approximately $89 million and requires substantial additional capital to continue as a going concern. There is substantial doubt about the company's ability to continue operations without further financing.
- Section 409A Tax Contingency: An internal review identified potential non-compliance with Section 409A of the Internal Revenue Code regarding stock options granted between 1998 and 2009. The company has accrued $550,000 for this liability, with an estimated potential additional exposure of up to $500,000.
- Clinical Development: Phase II-b clinical trials for Oxycyte (traumatic brain injury) are ongoing in Switzerland, Israel, and India. The company received a $2.07 million cost-reimbursement award from the U.S. Army in March 2011 for safety studies.
- Commercialization: Dermacyte products are being sold in the U.S. and Europe. New distribution agreements were signed for Switzerland, Russia, and Mexico.
- Risks: Key risks include the inability to raise additional capital, delays in clinical trials, regulatory hurdles (FDA clinical hold on previous protocols), and potential tax liabilities from the 409A review.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $522,340 cash balance and the $2.1 million remaining under the Note Purchase Agreement to fund operations beyond June 30, 2011.
- Debt Obligations: Review the terms of the Vatea Fund notes, specifically the $3.0 million final payment premium due at maturity (October 2013) and the effective interest rates (approx. 15-17%).
- 409A Liability: Monitor the outcome of the ongoing Section 409A investigation to determine if the accrued $550,000 is sufficient or if the additional $500,000 exposure materializes.
- Revenue Sustainability: Assess the durability of the 156% revenue increase, which was partially driven by a single initial order from a new distributor and the launch of cosmetic products, rather than core pharmaceutical revenue.
- Inventory Valuation: Confirm the status of the Oxycyte inventory impairment and future manufacturing costs for clinical trials.